Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
- 1 June 2005
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16_suppl) , 3508
- https://doi.org/10.1200/jco.2005.23.16_suppl.3508
Abstract
3508 Background: Cetuximab (Cetux), a monoclonal antibody (mab) that targets the epidermal growth factor receptor (EGFR), has shown antitumor activity both alone and in combination with irinotecan (IRI) in IRI-refractory colorectal cancer (CRC). Bevacizumab (Bev), a mab against vascular endothelial growth factor (VEGF), improved the response rate, PFS, and overall survival in CRC patients treated with first line IFL. We evaluated the safety and efficacy of concurrent administration of these two monoclonal antibodies in patients with metastatic CRC. Methods: This is a randomized phase II study in patients with IRI-refractory CRC. All patients were naive to both bev and cetux. EGFR expression was not required for study entry. Arm A received IRI at the same dose and schedule as last received prior to study, plus Cetux 400 mg/m2 loading dose, then weekly at 250 mg/m2, plus Bev 5 mg/kg given every other week. Arm B received the same Cetux and Bev as arm A, but without IRI. Results: 76 patients have been random...Keywords
This publication has 0 references indexed in Scilit: